New Schizophrenia Treatment Regulates Dopamine to Reduce Side Effects and Improve Adherence

Schizophrenia, a severe and complex mental health disorder, typically emerges in individuals' early twenties, disrupting their independence, relationships, education, and social lives. Dr. Yoav Domany, head of the men's psychiatric department at Ma'ayanei Hayeshua Medical Center, explains that schizophrenia affects about 1% of the population and causes significant functional impairment beyond hallucinations and delusions. Patients often struggle to maintain normal lives and require extensive support from rehabilitation services and family.

A major challenge in treating schizophrenia is patients' lack of insight into their illness, which leads to poor medication adherence. Traditional antipsychotic drugs, developed in the 1960s and 1970s, block dopamine receptors to control psychotic symptoms but cause severe side effects such as muscle stiffness and metabolic syndrome, including weight gain, cholesterol issues, diabetes, and hypertension. These side effects accumulate over years, often prompting patients to discontinue treatment.

Recently, a new class of treatments approved in the US and Israel offers a breakthrough by modulating dopamine activity indirectly through the acetylcholine system rather than blocking dopamine receptors outright. Dr. Domany describes this approach as more adaptive, allowing dopamine transmission to be regulated "as needed," which varies between individuals and over time. Clinical studies show this new treatment matches the efficacy of existing drugs in controlling positive symptoms like hallucinations and delusions but with a different and more tolerable side effect profile.

The new treatment's side effects mainly involve gastrointestinal discomfort during the initial weeks, which tend to subside, potentially enabling patients to maintain long-term therapy with fewer burdens. Dr. Domany cautiously notes that while improvements in negative symptoms such as motivation and social functioning are possible, more evidence is needed. However, the reduced side effect burden could significantly enhance treatment adherence and help patients sustain more stable and active lives alongside their illness.

This development represents a promising shift in schizophrenia management, focusing on balancing symptom control with quality of life improvements for patients and their families. The article emphasizes that medical advice should always be sought from qualified professionals.